Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2008 3
2009 3
2010 7
2011 23
2012 61
2013 70
2014 107
2015 123
2016 137
2017 138
2018 190
2019 170
2020 141
2021 27
Text availability
Article attribute
Article type
Publication date

Search Results

1,055 results
Results by year
Filters applied: . Clear all
Page 1
Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate.
Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, Senter PD, Alley SC. Okeley NM, et al. Clin Cancer Res. 2010 Feb 1;16(3):888-97. doi: 10.1158/1078-0432.CCR-09-2069. Epub 2010 Jan 19. Clin Cancer Res. 2010. PMID: 20086002 Free article.
The bystander activity of SGN-35 was determined using mixed tumor cell cultures consisting of CD30(+) and CD30(-) lines. ...This provides mechanistic insight into the pronounced preclinical and clinical antitumor activities observed with SGN-35....
The bystander activity of SGN-35 was determined using mixed tumor cell cultures consisting of CD30(+) and CD30(-) lines. ...Th …
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Younes A, et al. N Engl J Med. 2010 Nov 4;363(19):1812-21. doi: 10.1056/NEJMoa1002965. N Engl J Med. 2010. PMID: 21047225 Free article. Clinical Trial.
To enhance the antitumor activity of CD30-directed therapy, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-specific monoclonal antibody by an enzyme-cleavable linker, producing the antibody-drug conjugate brentuximab vedotin (SGN- …
To enhance the antitumor activity of CD30-directed therapy, the antitubulin agent monomethyl auristatin E (MMAE) was attached to a CD30-spec …
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, Yang Y, Sievers EL, Kennedy DA, Shustov A. Pro B, et al. J Clin Oncol. 2012 Jun 20;30(18):2190-6. doi: 10.1200/JCO.2011.38.0402. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614995 Clinical Trial.
A phase II multicenter trial was conducted to evaluate the efficacy and safety of brentuximab vedotin in patients with relapsed or refractory systemic ALCL. PATIENTS AND METHODS: Patients with systemic ALCL and recurrent disease after at least one prior therapy rece …
A phase II multicenter trial was conducted to evaluate the efficacy and safety of brentuximab vedotin in patients with relapse …
Brentuximab Vedotin (SGN-35).
Katz J, Janik JE, Younes A. Katz J, et al. Clin Cancer Res. 2011 Oct 15;17(20):6428-36. doi: 10.1158/1078-0432.CCR-11-0488. Clin Cancer Res. 2011. PMID: 22003070 Free article.
Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) directed against the CD30 antigen expressed on Hodgkin lymphoma and anaplastic large cell lymphoma. ...The elimination of T regulatory cells that inhibit cytotoxic effector cells and elim
Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) directed against the CD30 antigen expressed on
Brentuximab vedotin in T-cell lymphoma.
Van Der Weyden C, Dickinson M, Whisstock J, Prince HM. Van Der Weyden C, et al. Expert Rev Hematol. 2019 Jan;12(1):5-19. doi: 10.1080/17474086.2019.1558399. Epub 2018 Dec 18. Expert Rev Hematol. 2019. PMID: 30526166 Review.
Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting agent monomethylauristatin E. ...Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-ce
Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule-disrupting a
Brentuximab vedotin in the treatment of CD30+ PTCL.
Barta SK, Gong JZ, Porcu P. Barta SK, et al. Blood. 2019 Dec 26;134(26):2339-2345. doi: 10.1182/blood.2019001821. Blood. 2019. PMID: 31697814
The development of brentuximab vedotin has opened a new era in the management of peripheral T-cell lymphomas (PTCLs). The improved outcomes with brentuximab vedotin (BV) in combination with cyclophosphamide, doxorubicin, and prednisone (BV-CHP) vs cycl …
The development of brentuximab vedotin has opened a new era in the management of peripheral T-cell lymphomas (PTCLs). The impr …
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
Scott LJ. Scott LJ. Drugs. 2017 Mar;77(4):435-445. doi: 10.1007/s40265-017-0705-5. Drugs. 2017. PMID: 28190142 Free PMC article. Review.
In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin resulted in high objective response (complete plus partial remission) rates in patients with relapsed or refractory CD30-positive HL, including as retreatment i …
In noncomparative, phase 2 trials and in the real-world setting, salvage therapy with brentuximab vedotin resulted in high obj …
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Straus DJ, Długosz-Danecka M, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero-Torres A, Gallamini A. Straus DJ, et al. Blood. 2020 Mar 5;135(10):735-742. doi: 10.1182/blood.2019003127. Blood. 2020. PMID: 31945149 Clinical Trial.
The phase 3 ECHELON-1 study demonstrated that brentuximab vedotin (A) with doxorubicin, vinblastine, and dacarbazine (AVD; A+AVD) exhibited superior modified progression-free survival (PFS) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for frontline …
The phase 3 ECHELON-1 study demonstrated that brentuximab vedotin (A) with doxorubicin, vinblastine, and dacarbazine (AVD; A+A …
Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies.
Ng SY, Jacobsen ED. Ng SY, et al. Hematol Oncol Clin North Am. 2019 Aug;33(4):657-668. doi: 10.1016/j.hoc.2019.04.002. Epub 2019 May 18. Hematol Oncol Clin North Am. 2019. PMID: 31229161 Review.
Therapeutic advances for peripheral T-cell non-Hodgkin lymphoma (PTCL) have lagged behind their B-cell NHL counterparts in part because novel agents to treat PTCL have been developed empirically. The recent clinical success of brentuximab-vedotin suggests that novel …
Therapeutic advances for peripheral T-cell non-Hodgkin lymphoma (PTCL) have lagged behind their B-cell NHL counterparts in part because nove …
1,055 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page